The Market
pVADS are implanted to provide temporary mechanical circulatory support to assist or completely offload the native pumping action of the heart to improve mortality and morbidity associated with cardiac diseases.
The current US market is $1.8B growing at 18% year over year monopolized by one manufacturer having acquired Abiomed in 2022 for $16.6B.
Current Clinical Applications
Emerging Clinical Applications
ST Elevated Myocardial Infarction (STEMI)
STEMI is a type of heart attack having a unique electrical conduction that is a life threatening, time-sensitive emergency that requires intervention. Landmark clinical trial data demonstrating the safety and effectiveness of pVAD therapy for this indication is estimated to be reported in 1H 2026.
